Synthesis of peptides
Scheme S1. The final synthetic steps for RCM macrocyclized 3 10 -helical peptides
Fmoc-Ser(Al)-OH
Boc-Ser(Al)-OH 1 (1.0 g, 4.1 mmol) was dissolved in DCM and cooled to 0 o C. TFA (2 ml) was added and the mixture was stirred at 0 o C for 30 min and then warmed to room temperature over an additional 30 min. The volatiles were removed and the resulting residue was dissolved in dioxane (5mL). A solution of 10% NaOH (163 mg in 1.63 mL H 2 O, 4.1 mmol, 1 equiv.) was added followed by NaHCO 3 (343 mg, 4.1 mmol, 1 equiv.) and Fmoc-OSu (1.37 g, 4.1 mmol, 1 equiv.). The reaction mixture was stirred overnight at room temperature after which the volatiles were removed under reduced pressure. The residue was dissolved in 2.5% NaHCO 3 and washed with Et 2 O (3x20 mL). The aqueous layer was then acidified to pH 3 by dropwise addition of 6 M aqueous HCl and extracted with EtOAc (3x20 mL). The combined organic layers were washed with brine (20 mL), dried over Na 2 SO 4 and the solvent removed under reduced pressure to give the product as a white solid (1.36 g, 91%). 1 
Peptide 26
Fmoc-Aib-OH loaded 2-chlorotrityl chloride resin (2.00 g, typically 0.5 mmol/ gram of resin) was transferred into a sintered funnel fitted with a Teflon stopcock, and then rinsed with DCM (2x20 mL). After air drying, the Fmoc group was removed by reaction with a solution of 25% piperidine in DMF (20 mL) for 30 min followed by washing successively with DCM (3x20 mL), DMF (3 x 20 mL), and DCM (3 x 20 mL). To a solution of Fmoc-Ser(Al)-OH (1.00 g, 2 equiv) in DMF (4 mL) was added a 0.5 M solution of HATU in DMF (2 mL) followed by DIPEA (1.2 mL, 4-fold excess) and the resulting solution was added to the deprotected resin. The mixture was left for 2 h, with occasional stirring. The resin was isolated by filtration and rinsed successively with DCM (3 x 50 mL), DMF (3 x 50 mL), and DCM (3 x 50 mL). The sequence was repeated 2 more times to ensure complete coupling. Following additions of Fmoc-Aib-OH and Fmoc-Ser(Al)-OH were carried out, using this protocol, to give the appropriate pentapeptide. The pentapeptide was capped with Boc-Aib-OH in the last cycle using the same protocol and the resulting hexapeptide was cleaved from the resin with 2% TFA / DCM (v/v). The crude products were purified by HPLC. 1 
Peptide 22
(E isomer) Peptide 26 (0.839 g, 1.2 mmol) was dissolved in anhydrous DCM (60 mL) in a nitrogen-flushed flask equipped with a water-cooled condenser. Second-generation Grubbs' catalyst (0.071 g, 7 mol%) was added in a single portion and the flask was then immersed in an oil bath maintained at 50 °C. After refluxing for 30 min., the reaction was quenched by adding ethyl vinyl ether (400µL) directly to the flask after removing it from the oil bath. Stirring continued for 20 min., after which the solvent was removed under reduced pressure. The residue was purified by column chromatography (DCM with 2% →10% methanol) to afford the E-selective isomer (475 mg, 57%). 1 
Peptide 23
To a solution of 22 (100 mg, 0.146 mmol) in anhydrous ethyl acetate (30 mL), was added 20 mg Pd/C (20% w/w). The reaction was purged with nitrogen and then placed under a hydrogen atmosphere. After stirring for 2 h, the reaction was filtered and concentrated in vacuo to reveal a white solid (100 mg, quant). 1 
Peptide 10
(E isomer) Peptide 22 (78 mg, 0.11 mmol) and ferrocenylmethylamine (35 mg, 0.16 mmol) were dissolved in anhydrous DMF (3 mL). DIPEA (80µL, 4 equiv.), HOAt (50mg, 2 equiv.) and HATU (4 equiv.) were added. Reaction mixture was stirred overnight under an N 2 atmosphere at rt. The solvent was removed in vacuo and the peptide purified using reverse phase HPLC. 1 
Peptide 24
Fmoc-Aib-OH loaded 2-chlorotrityl chloride resin (2.0 g, typically 0.5 mmol/ gram of resin) was transferred into a sintered funnel fitted with a Teflon stopcock, and then rinsed with DCM (2x20 mL). After air drying, the Fmoc group was removed by reaction with a solution of 25% piperidine in DMF (20 mL) for 30 min followed by washing successively with DCM (3x20 mL), DMF (3 x 20 mL), and DCM (3 x 20 mL). To a solution of Fmoc-Aib-OH (1.0 g, 2 equiv) in DMF (4 mL) was added a 0.5 M solution of HATU in DMF (2 mL) followed by DIPEA (1.2 mL, 4-fold excess) and the resultant solution was added to the deprotected resin. The mixture was left for 2 h, with occasional stirring. The resin was isolated by filtration and rinsed successively with DCM (3 x 50 mL), DMF (3 x 50 mL), and DCM (3 x 50 mL). The sequence was repeated twice to ensure complete coupling. Successive additions of Fmoc Aib-OH were carried out to give the appropriate oligotetrapeptide. Following additions of Fmoc-Ser(Al)-OH were carried out, using this protocol, to give the appropriate pentapeptide. The pentapeptide was then capped with BocAib-OH in the last cycle using the same protocol and the resulting hexapeptide was cleaved from the resin with 2% TFA / DCM (v/v). The crude products were purified using reverse phase HPLC. 1 
Peptide 13
Peptide 24 (460 mg, 0.69 mmol) and ferrocenylmethylamine (163 mg, 0.76 mmol) were dissolved in anhydrous DMF (10 mL). DIPEA (480 µL, 4 equiv.), HOAt (190 mg, 2 equiv.) and HATU (4 equiv.) were added. Reaction mixture was stirred overnight under an N 2 atmosphere at room temperature. The solvent was removed in vacuo and the peptide purified using reverse phase HPLC. 1 
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Scheme S3. The final synthetic steps for helical control 6
Peptide 15
Peptide 26 (240 mg, 0.32 mmol) and ferrocenylmethylamine (88 mg, 0.41 mmol) were dissolved in anhydrous DMF (5 mL). DIPEA (240µL, 4 equiv.), HOAt (80 mg, 2 equiv.) and HATU (4 equiv.) were added. The reaction mixture was stirred overnight under an N 2 atmosphere at room temperature. The solvent was removed in vacuo and the peptide purified using reverse phase HPLC. 1 3 (584 mg, 1.13 mmol) was dissolved in THF (4 mL). To this stirring reaction 1.6M NaOH (1.2 mL) was added, followed by MeOH (2 mL). The solution was stirred at rt for 22 h, diluted with water (20 mL) and ethyl acetate (20 mL), and the pH adjusted to pH 3. The organic phase was separated, washed with brine (20 mL), and dried with MgSO 4 . The solvent was removed in vacuo to yield a white crystalline solid (495 mg, 87%). 1 3 (558 mg, 1.08 mmol) was dissolved in THF (3.2 mL). To this stirring reaction, 1.6M NaOH (1.1 mL) was added, followed by MeOH (1.84 mL). The solution was stirred at rt for 22 h, diluted with water (20 mL) and ethyl acetate (20 mL), and the pH adjusted to pH 3-4. The organic phase was separated, washed with brine (20 mL), and dried with MgSO 4 . The solvent was removed in vacuo to yield a white solid (400 mg, 73%). 1 
Peptide 29

Methyl(2S)-2-[(2S)-2-[(2S)-2-{[(tert-butoxy)carbonyl]amino}-3-[4-(prop-2-en-1-yloxy)phenyl]
propanamido]-4-methylpentanamido]pent-4-enoate 3 (485 mg, 0.89 mmol) was dissolved in THF (3 mL). To this stirring reaction 1.6M NaOH (890 μL) was added, followed by MeOH (1.5 mL). The solution was stirred at rt for 23 h, diluted with water (20 mL) and ethyl acetate (20 mL), and the pH adjusted to pH 3-4. The organic phase was separated, washed with brine (20 mL), and dried over MgSO 4 . The solvent was removed in vacuo to yield a white solid (405 mg, 86%). 1 
Peptide 9
Peptide 29 (200 mg, 0.38 mmol) was dissolved in anhydrous DMF (6.4 mL). Ferrocenylmethylamine (90 mg, 0.42 mmol) was added, followed by DIPEA (196 mg, 1.52 mmol, 265 μL), HATU (160 mg, 0.42 mmol) and HOAt (57 mg, 0.42 mmol). The reaction mixture was stirred under an N 2 atmosphere at rt for 24 h, and subsequently diluted with water (30 mL) and ethyl acetate (30 mL), and the pH adjusted to pH 3-4. The organic phase was separated and washed with NaHCO 3 (30 mL) and brine (30 mL), and dried with MgSO 4 . The solvent was removed in vacuo to yield Peptide 18 as a brown solid (280 mg), that was used in the next step without further purification. Peptide 18 (37 mg, 0.05 mmol) was dissolved in TFE (3 mL) and 4M HCl in dioxane (2.5 mL) added. The mixture was stirred at rt for 25 min., and the solvent removed in vacuo. The crude product was purified using reverse phase HPLC to yield a brown solid (Peptide 9, (15 mg, 46%) Note: * This distance is defined between the C atom (i) and N (i+3). This is indicative of an optimal extended β-strand, as shown in Figure S19 . 6. Diabatic potential profiles in the three model peptides 
